logo-loader
IG Group

Analysts more upbeat on IG Group after trading update

Liberum upgraded its recommendation for the online broker to 'buy' from 'hold'

spreadbet
IG plans to invest £30mln a year to generate an additional £100mln of revenue by 2022

Liberum Capital has upgraded its rating for IG Group Holdings PLC (LON:IGG) to 'buy' from 'hold' after the online broker unveiled “stunning” new medium-term growth targets.

On Wednesday, the FTSE 250-listed group said it expected to generate an additional £100mln of revenue by 2022 by upping spending by £30mln a year to take advantage of opportunities in new products and territories.

READ: IG Group makes long-term dividend commitment as trading activity picks up

This, plus growth of 3-5% in its core business, would see revenue in 2022 around 30% higher and earnings around 50% higher than the past and coming year, the firm added.

In a note to clients, Liberum analyst Ben Williams said that while IG's fourth-quarter update was “weakish”, he was very much impressed by IG’s willingness to pour investment into achieving the new targets “and by a steadfast holding of a barely covered dividend”.

Taking the new targets as the base for its numbers, but acknowledging that the market is expected to see considerable execution risk, Williams trimmed his share price target for IG to 687p from 693p, based on a multiple of 14 times his 2021 forecast earnings. 

But, he said: “With an 8% yield on top, and that upside/downside, the stock is already clearly a buy, hence we upgrade our recommendation."

Peel Hunt also ups target

Broker Peel Hunt also upgraded its forecasts for IG by 5% and hiked its target price to 650p from 620p, keeping a 'buy’ rating on the stock. 

“We take a cautious approach to the targets as we observe the execution, with potential for upside,” analyst Anthony Da Costa said.

After jumping around 14% higher after the trading update, IG shares were up another 1% on Thursday to 539.8p.

Quick facts: IG Group

Price: £5.52

Market: LSE
Market Cap: £2.04 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

1 day, 9 hours ago

RNS

Notice of AGM

1 day, 20 hours ago

Annual Financial Report

5 days, 20 hours ago

Director/PDMR Shareholding

1 week, 3 days ago

Total Voting Rights

2 weeks, 4 days ago

Director/PDMR Shareholding

2 weeks, 4 days ago

Director/PDMR Shareholding

3 weeks, 3 days ago

Additional Listing

3 weeks, 4 days ago

Block listing Interim Review

3 weeks, 4 days ago

2 min read